Celecoxib
Other / unclassified targets ABCB1, CYP2D6, GATA6, PTGS2 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 9 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (6) | US (FDA) | CELEBREX | — | 2001-10-18 – 2018-06-28 | fda.gov ↗ |
| Withdrawn | EU (EMA) | Onsenal | — | 2008-11-28 | europa.eu ↗ |
| Approved | EU (EMA) | Onsenal | — | 2003-10-17 | europa.eu ↗ |
| Approved | US (FDA) | CELEBREX | — | 1998-12-31 | fda.gov ↗ |
Trials 398 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 09 trials | ||||||
| Phase 0 | NCT06942039 | Sep 2025 → Dec 2030 expected | atypical teratoid rhabdoid tumor, childhood medulloblastoma, embryonal tumor with multilayered rosettes, ependymoblastoma +5 | C17 Council | Recruiting | No outcome recorded |
| Phase 0 | NCT04648540 | Dec 2020 → Aug 2022 | — | Cairo University | Completed | No outcome recorded |
| Phase 0 | NCT03820193 | Jan 2019 → Jun 2020 | substance-related disorder | Henry Ford Health System | Completed | No outcome recorded |
| Phase 0 | NCT03599453 | Jan 2019 → Sep 2020 | triple-negative breast carcinoma | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 0 | NCT02362529 | Feb 2015 → Apr 2019 | major depressive disorder | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| Phase 0 | NCT01901679 | Jul 2013 → Aug 2014 | obesity disorder | Rockefeller University | Completed | No outcome recorded |
| Phase 0 | NCT01796951 | Feb 2013 → Feb 2016 | nicotine dependence | Vanderbilt University | Completed | No outcome recorded |
| Phase 0 | NCT01881048 | Dec 2009 → Jan 2014 | female breast carcinoma | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 0 | NCT00585156 | Jun → Sep 2008 | — | University of Utah | Terminated | No outcome recorded |
| Phase 157 trials | ||||||
| Phase 1 | NCT07338266 | Jan → Dec 2026 expected | osteoarthritis, knee | Avidence Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT06076837 | Jan → Dec 2025 | pancreatic adenocarcinoma | HonorHealth Research Institute | Terminated | No outcome recorded |
| Phase 1 | NCT05281276 | Sep 2022 → Mar 2024 | colorectal cancer | Taipei Medical University Shuang Ho Hospital | Terminated | No outcome recorded |
| Phase 1 | NCT05438303 | Jun → Dec 2022 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05512013 | Feb 2022 → Apr 2023 | bone resorption disease, disease of bone structure | United States Army Research Institute of Environmental Medicine | Completed | No outcome recorded |
| Phase 1 | NCT04120636 | Mar 2021 → Jun 2024 | central serous chorioretinopathy, hyalitis, macular retinal edema, occlusion of tributary of retinal vein +1 | Targeted Therapy Technologies, LLC | Unknown | No outcome recorded |
| Phase 1 | NCT04526197 | Jul → Nov 2020 | Wilson disease | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04490434 | Jun → Aug 2020 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT04375865 | May → Jul 2020 | — | Addpharma Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03878524 | Apr → Dec 2020 | acute myeloid leukemia, atypical chronic myeloid leukemia, BCR-ABL1 negative, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, castration-resistant prostate carcinoma +14 | OHSU Knight Cancer Institute | Terminated | No outcome recorded |
| Phase 1 | NCT04090684 | Dec 2019 → Sep 2021 | amyotrophic lateral sclerosis | NeuroSense Therapeutics Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04081389 | Dec 2019 → May 2022 | breast carcinoma in situ, triple-negative breast carcinoma | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT04041050 | Nov 2019 → Dec 2026 expected | myeloproliferative neoplasm | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03876210 | Jul 2019 | arthritic joint disease | PMG Pharm Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03912428 | Jun 2019 → Jun 2024 | idiopathic inflammatory myopathy, rheumatoid arthritis | National Institute of Mental Health (NIMH) | Terminated | No outcome recorded |
| Phase 1 | NCT03728179 | Jan 2019 → Oct 2023 | cancer | Centre Hospitalier Universitaire Vaudois | Completed | No outcome recorded |
| Phase 1 | NCT03822520 | Jun 2017 → May 2018 | — | Samsung Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT03282838 | Jun → Aug 2017 | migraine disorder | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 1 | NCT02885974 | Dec 2016 → Mar 2024 | urinary bladder cancer | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT02711579 | May 2016 → Apr 2017 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT06004947 | Jan → Mar 2016 | anti-neutrophil cytoplasmic antibody-associated vasculitis | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT02502006 | Nov 2015 → Sep 2022 | — | University of Pennsylvania | Terminated | No outcome recorded |
| Phase 1 | NCT02602509 | Nov 2015 → Feb 2016 | tuberculosis | National University Hospital, Singapore | Completed | No outcome recorded |
| Phase 1 | NCT03051685 | Jul → Aug 2015 | — | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 1 | NCT02502500 | Jul 2015 | — | Akebia Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02131012 | Jun 2015 → Nov 2016 | — | Vanderbilt University | Terminated | No outcome recorded |
| Phase 1 | NCT02401295 | May → Aug 2015 | plasma cell myeloma | University of Iowa | Completed | No outcome recorded |
| Phase 1 | NCT02115074 | Jun 2014 → Nov 2018 | glioma | Centre Oscar Lambret | Completed | No outcome recorded |
| Phase 1 | NCT02084511 | Mar → Oct 2014 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02037165 | Jan → Apr 2014 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02030964 | Jan 2014 → Dec 2023 | neuroblastoma | New Approaches to Neuroblastoma Therapy Consortium | Completed | No outcome recorded |
| Phase 1 | NCT01705106 | Aug 2012 → Feb 2016 | cancer of unknown primary site | University of Chicago | Terminated | No outcome recorded |
| Phase 1 | NCT01549743 | May → Jun 2012 | — | Hanlim Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01258868 | Dec 2010 → Jun 2016 | esophageal cancer, lung cancer, mesothelioma, sarcoma +1 | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT01020279 | Oct 2009 → Jan 2010 | musculoskeletal system disorder | X-pert Med GmbH | Completed | No outcome recorded |
| Phase 1 | NCT00104767 | Jan 2009 → Oct 2014 | lung cancer | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00729495 | Jul → Aug 2008 | — | POZEN | Completed | No outcome recorded |
| Phase 1 | NCT00700687 | Jun → Jul 2008 | — | POZEN | Completed | No outcome recorded |
| Phase 1 | NCT00400374 | Aug 2007 → Dec 2012 | head and neck cancer | Emory University | Completed | No outcome recorded |
| Phase 1 | NCT00177853 | Dec 2006 | malignant pancreatic neoplasm | University of Pittsburgh | Terminated | No outcome recorded |
| Phase 1 | NCT00296127 | Feb → Mar 2006 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00290680 | Mar 2005 → Jan 2009 | cancer of unknown primary site | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 1 | NCT00084721 | Mar → Oct 2005 | colorectal cancer, diarrheal disease | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT00108186 | Oct 2004 → Jun 2010 | non-small cell lung carcinoma | US Department of Veterans Affairs | Withdrawn | No outcome recorded |
| Phase 1 | NCT00450736 | Mar 2004 → May 2009 | childhood malignant neoplasm, sarcoma | University of Miami | Completed | No outcome recorded |
| Phase 1 | NCT00088959 | Dec 2003 → Jan 2009 | non-small cell lung carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00075673 | Nov 2003 → Sep 2004 | breast cancer | Case Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT00346801 | Sep 2003 → Oct 2012 | lung cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00072072 | Aug 2003 → Jan 2006 | lung cancer | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00328432 | Jun 2003 → Dec 2005 | breast cancer | University of Kansas | Completed | No outcome recorded |
| Phase 1 | NCT00070057 | Apr 2003 → Feb 2010 | female breast carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00685568 | Nov 2002 → Apr 2006 | colorectal cancer, precancerous condition | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00037817 | May 2002 → Oct 2008 | esophageal cancer, non-small cell lung carcinoma, pleural mesothelioma, small cell lung carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00223691 | Mar 2002 → Jan 2017 | autonomic nervous system disorder, orthostatic hypotension | Vanderbilt University | Completed | No outcome recorded |
| Phase 1 | NCT00551005 | Dec 2001 → Feb 2012 | cancer of unknown primary site | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00551889 | Sep 2001 → Feb 2012 | cancer of unknown primary site | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00001693 | Mar 1998 → Jan 2002 | hereditary nonpolyposis colon cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/225 trials | ||||||
| Phase 1/2 | NCT03686657 | Dec 2026 → Dec 2030 | arthritic joint disease, hypertensive disorder, obesity disorder, type 2 diabetes mellitus | ARKAY Therapeutics | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT07632235 | Jul 2026 → Dec 2029 expected | intrahepatic cholangiocarcinoma | Shanghai 6th People's Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05756166 | Feb 2024 → Apr 2025 | female breast carcinoma, triple-negative breast carcinoma | Roswell Park Cancer Institute | Terminated | No outcome recorded |
| Phase 1/2 | NCT05476679 | Sep 2022 → Jun 2023 | — | Raziel Therapeutics Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT02770378 | Nov 2016 → Oct 2018 | glioblastoma | University of Ulm | Completed | No outcome recorded |
| Phase 1/2 | NCT02054104 | Sep 2014 → Jun 2015 | melanoma, respiratory system cancer, sarcoma, thoracic cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1/2 | NCT02151448 | Jul 2014 → Feb 2019 | malignant pancreatic neoplasm, malignant peritoneal mesothelioma, peritoneal carcinomatosis | David Bartlett | Completed | No outcome recorded |
| Phase 1/2 | NCT01545141 | Oct 2012 → Apr 2016 | colorectal carcinoma | Roswell Park Cancer Institute | Terminated | No outcome recorded |
| Phase 1/2 | NCT01280006 | Jan → Dec 2011 | hypertensive disorder, obstructive sleep apnea syndrome, stroke disorder | University of Calgary | Completed | No outcome recorded |
| Phase 1/2 | NCT01021215 | May 2010 → Aug 2012 | nicotine dependence | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00953849 | Nov 2009 → Dec 2015 | oral cavity cancer | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 1/2 | NCT01769625 | Jan 2009 → Nov 2016 | breast cancer | Hartford Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT01425476 | Jul 2008 → Nov 2016 | breast cancer | Hartford Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT00970502 | Feb 2007 → Nov 2010 | larynx cancer, paranasal sinus neoplasm, pharynx cancer | Johnny Kao | Completed | No outcome recorded |
| Phase 1/2 | NCT00314262 | Oct 2006 → Nov 2012 | precancerous condition | Emory University | Completed | No outcome recorded |
| Phase 1/2 | NCT00357617 | Jun 2006 → ? | head and neck cancer | Centre Hospitalier Universitaire Vaudois | Unknown | No outcome recorded |
| Phase 1/2 | NCT00293436 | Jan 2005 → ? | liver cancer | University of California, San Francisco | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00159484 | Oct 2004 → Jan 2015 | colon carcinoma | University of Southern California | Completed | No outcome recorded |
| Phase 1/2 | NCT00188565 | Mar 2004 → Mar 2009 | colorectal neoplasm | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 1/2 | NCT00212108 | Nov 2003 → Mar 2007 | nasopharyngeal carcinoma | National University Hospital, Singapore | Completed | No outcome recorded |
| Phase 1/2 | NCT00073866 | Jun 2003 → Dec 2004 | lung cancer | Northwestern University | Completed | No outcome recorded |
| Phase 1/2 | NCT00581971 | Sep 2002 → Dec 2007 | cancer | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 1/2 | NCT00046839 | Jul 2002 → Sep 2011 | lung cancer | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 1/2 | NCT00023660 | Aug 2001 → Jan 2005 | cervical cancer | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 1/2 | NCT00152828 | Feb 2001 → Jan 2011 | cervical carcinoma | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2150 trials | ||||||
| Phase 2 | NCT07139405 | Sep 2026 → Sep 2027 expected | type 2 diabetes mellitus | Myopharm Limited | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07597902 | Jun 2026 → Jun 2028 expected | long COVID-19 | Icahn School of Medicine at Mount Sinai | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07494565 | Mar → Dec 2026 expected | diffuse large B-cell lymphoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07174570 | Jan → Nov 2026 expected | hepatocellular carcinoma | Emory University | Recruiting | No outcome recorded |
| Phase 2 | NCT07150949 | Aug 2025 → Aug 2027 expected | — | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT07104266 | Aug 2025 → Aug 2028 expected | triple-negative breast carcinoma | University of Sherbrooke | Recruiting | No outcome recorded |
| Phase 2 | NCT07049185 | Jul 2025 → Mar 2027 expected | esophageal squamous cell carcinoma | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06997068 | Jul 2025 → Jun 2028 expected | hypopharyngeal carcinoma, laryngeal carcinoma, oral cavity carcinoma, oropharyngeal carcinoma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT06903858 | Jun 2025 → Apr 2028 expected | colorectal cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06505187 | Feb 2025 → Sep 2026 expected | — | University of Wisconsin, Madison | Recruiting | No outcome recorded |
| Show all 150 trials opens the full record — a long page | ||||||
| Phase 2/310 trials | ||||||
| Phase 2/3 | NCT04860635 | Jan 2027 → Jul 2028 | — | Arthritis Innovation Corporation | Suspended | No outcome recorded |
| Phase 2/3 | NCT05509946 | Oct 2022 → Apr 2023 | — | Indonesia University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03825809 | Jan 2019 → Jan 2020 overdue | substance-related disorder | Henry Ford Health System | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03818932 | Jan 2019 → Jan 2020 | — | Henry Ford Health System | Completed | No outcome recorded |
| Phase 2/3 | NCT00808743 | May 2009 → Jul 2011 | classic familial adenomatous polyposis, intestinal polyp, tumor of duodenum | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 2/3 | NCT00934739 | Jun 2007 → Dec 2012 | oral cavity cancer | National Health Research Institutes, Taiwan | Terminated | No outcome recorded |
| Phase 2/3 | NCT00268476 | Jul 2005 → Mar 2026 overdue | prostate cancer | Medical Research Council | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT00136487 | Oct 2002 → Sep 2006 | prostate cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2/3 | NCT00027976 | Dec 2001 → Dec 2005 | precancerous condition | University of Alabama at Birmingham | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT00006124 | Jun 2000 → Mar 2006 | bladder transitional cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 357 trials | ||||||
| Phase 3 | NCT06863636 | Sep 2024 → Oct 2025 overdue | osteoarthritis, hip, osteoarthritis, knee | Laboratorios Silanes S.A. de C.V. | Recruiting | No outcome recorded |
| Phase 3 | NCT06516094 | Apr 2024 → Jan 2025 | chronic pain syndrome | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 3 | NCT06285617 | Apr 2024 → Jan 2025 | subacute thyroiditis | Xinqiao Hospital of Chongqing | Unknown | No outcome recorded |
| Phase 3 | NCT05603832 | Nov 2022 → Nov 2023 | — | Arthritis Innovation Corporation | Completed | No outcome recorded |
| Phase 3 | NCT05415397 | Sep 2022 → Jul 2026 overdue | major depressive disorder | Amsterdam UMC, location VUmc | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05362851 | Nov 2021 → Jan 2023 | osteoarthritis, knee | Yooyoung Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04429022 | Nov 2020 → May 2022 | — | State University of New York at Buffalo | Completed | No outcome recorded |
| Phase 3 | NCT04176419 | Jan 2020 → Jun 2021 | — | Case Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 3 | NCT03974932 | Jun 2019 → Dec 2020 | — | Heron Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT03586934 | Jun 2018 → Jun 2019 | substance-related disorder | Rush University Medical Center | Withdrawn | No outcome recorded |
| Phase 3 | NCT03062644 | Apr 2017 → Jun 2018 | — | Mundipharma Research GmbH & Co KG | Completed | No outcome recorded |
| Phase 3 | NCT03009019 | Dec 2016 → Nov 2017 | migraine disorder | BioDelivery Sciences International | Completed | No outcome recorded |
| Phase 3 | NCT02979197 | Nov 2016 → Jul 2017 | hypertensive disorder | Kitov Pharma Ltd | Completed | No outcome recorded |
| Phase 3 | NCT03059238 | Sep 2016 → Mar 2019 | liver cancer | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 3 | NCT02703363 | Aug 2016 → Dec 2018 | bipolar depression | Pakistan Institute of Living and Learning | Completed | No outcome recorded |
| Phase 3 | NCT02726659 | May 2016 → Jan 2019 | bipolar disorder, postpartum depression | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Terminated | No outcome recorded |
| Phase 3 | NCT02172040 | Jun 2014 → Nov 2015 | hypertensive disorder | Kitov Pharmaceuticals, Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02108366 | Mar 2014 → Mar 2018 | influenza | The University of Hong Kong | Completed | No outcome recorded |
| Phase 3 | NCT02537925 | Jan 2014 → Dec 2016 | nasopharyngeal carcinoma | Changjie Huang | Unknown | No outcome recorded |
| Phase 3 | NCT01858571 | Oct 2013 → Jul 2016 | childhood malignant neoplasm | All India Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01150045 | Jun 2010 → Feb 2020 | colorectal cancer | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 3 | NCT01118572 | Feb → Nov 2010 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 3 | NCT01041781 | Feb 2010 → Jan 2017 | lung cancer | Alliance for Clinical Trials in Oncology | Terminated | No outcome recorded |
| Phase 3 | NCT00976716 | Sep → Nov 2009 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00762463 | Jul 2009 → Jun 2010 | ankylosing spondylitis | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00809354 | Feb 2009 → Oct 2010 | osteoarthritis | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00549549 | Feb 2008 → Dec 2009 | gout | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00662558 | Jan → Sep 2008 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01017380 | Jan 2008 → Jan 2009 | — | Prince of Songkla University | Completed | No outcome recorded |
| Phase 3 | NCT00402987 | Dec 2006 → Nov 2007 | pharyngitis | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00585312 | Sep 2006 → Oct 2013 | classic or attenuated familial adenomatous polyposis | Viatris Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00295035 | Mar 2006 → Mar 2007 | colonic neoplasm | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT00305643 | Feb 2006 → Oct 2008 | breast cancer, colorectal cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 3 | NCT02429427 | Dec 2005 → Mar 2019 | female breast carcinoma | Imperial College London | Completed | No outcome recorded |
| Phase 3 | NCT00486460 | Jun 2005 → ? | pancreatic adenocarcinoma | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT00141154 | Oct 2004 → ? | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00150280 | Oct 2004 → Jul 2005 | neuropathy, painful | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00163241 | Jun 2004 → Jan 2006 | osteoarthritis | Viatris Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00092781 | Mar 2004 → Feb 2005 | osteoarthritis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092768 | Mar 2004 → Feb 2005 | osteoarthritis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00085163 | Mar 2004 → Nov 2005 | colorectal cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 3 | NCT00211952 | Mar 2004 → ? | non-small cell lung carcinoma | Medical University of Gdansk | Suspended | No outcome recorded |
| Phase 3 | NCT00525096 | Jul 2003 → Dec 2004 | breast cancer | ARCAGY/ GINECO GROUP | Completed | No outcome recorded |
| Phase 3 | NCT00064181 | May 2003 → Jan 2005 | colorectal cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 3 | NCT00092352 | Apr → Dec 2003 | osteoarthritis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00092365 | Apr → Nov 2003 | osteoarthritis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00101686 | Feb 2003 → Oct 2008 | colorectal neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00648141 | Jan 2003 → Jan 2005 | ankylosing spondylitis | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00050479 | Dec 2002 → Jul 2006 | macular degeneration | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 3 | NCT00137410 | Nov 2002 → Mar 2006 | osteoarthritis, knee | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00652925 | Oct 2002 → Apr 2004 | juvenile idiopathic arthritis | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00348452 | Sep 2002 → Aug 2003 | chronic pain syndrome | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00981201 | Nov 2001 → Jul 2007 | — | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00007189 | Jan 2001 → May 2007 | Alzheimer disease | Seattle Institute for Biomedical and Clinical Research | Completed | No outcome recorded |
| Phase 3 | NCT00009230 | Jun 2000 → Jun 2005 | amnestic disorder | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 3 | NCT00032890 | Apr 2000 → Feb 2004 | osteoarthritis | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 3 | NCT00005094 | Mar 2000 → Apr 2006 | colon carcinoma, rectal cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 461 trials | ||||||
| Phase 4 | NCT06699966 | Jun 2027 → Jun 2031 expected | major depressive disorder | Stony Brook University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07116564 | Aug 2025 → Aug 2026 overdue | — | Aga Khan University | Recruiting | No outcome recorded |
| Phase 4 | NCT07076069 | Jul 2025 → Jun 2028 expected | rotator cuff syndrome | Montefiore Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT06671002 | Jan 2025 → Oct 2026 expected | — | University of Michigan | Recruiting | No outcome recorded |
| Phase 4 | NCT06379425 | Mar 2024 → Mar 2026 overdue | — | Northwell Health | Recruiting | No outcome recorded |
| Phase 4 | NCT06159114 | Dec 2023 → Jan 2025 | chronic prostatitis | Xintian Pharmaceutical | Completed | No outcome recorded |
| Phase 4 | NCT05722002 | Feb 2023 → Dec 2026 expected | neuropathy, painful | University of Michigan | Recruiting | No outcome recorded |
| Phase 4 | NCT05288374 | Feb 2022 → Nov 2023 | — | Charles University, Czech Republic | Completed | No outcome recorded |
| Phase 4 | NCT04522206 | Aug 2020 → Jun 2021 | vertebral column disorder | NYU Langone Health | Completed | No outcome recorded |
| Phase 4 | NCT04259333 | Mar → Dec 2020 | neuropathy, painful, substance-related disorder | Blake Raggio | Unknown | No outcome recorded |
| Phase 4 | NCT04147013 | Feb 2020 → Feb 2026 overdue | aspirin-induced respiratory disease, chronic rhinosinusitis | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04015908 | Aug 2019 → Jan 2023 | substance-related disorder | University of Utah | Completed | No outcome recorded |
| Phase 4 | NCT03859024 | Mar 2019 → Apr 2023 | urethral stricture | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 4 | NCT03549611 | Aug 2018 → Jun 2019 | nephrolithiasis | Kevin J Flynn MD | Withdrawn | No outcome recorded |
| Phase 4 | NCT04814355 | Aug 2018 → Aug 2025 | major depressive disorder | Stony Brook University | Completed | No outcome recorded |
| Phase 4 | NCT03584074 | Jul 2018 → May 2019 | lumbar spinal stenosis | Seoul National University Bundang Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03190603 | Jun 2018 | spondyloarthropathy | Armed Forces Capital Hospital, Republic of Korea | Completed | No outcome recorded |
| Phase 4 | NCT03404479 | Jan 2018 → Jan 2019 | osteoarthritis, knee | Whan-Seok Choi | Unknown | No outcome recorded |
| Phase 4 | NCT03121963 | Nov 2017 → Nov 2020 | — | University of Alabama at Birmingham | Withdrawn | No outcome recorded |
| Phase 4 | NCT02160301 | Nov 2017 → Dec 2019 | — | University of North Carolina, Chapel Hill | Withdrawn | No outcome recorded |
| Phase 4 | NCT02739035 | Apr 2016 → Dec 2022 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT02780323 | Nov 2015 → Dec 2017 | rheumatoid arthritis | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT02961998 | Jul 2015 → Jul 2016 | hepatocellular carcinoma | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 4 | NCT02667730 | Jun 2015 → May 2019 | ligament disorder | Canadian Department of National Defence | Completed | No outcome recorded |
| Phase 4 | NCT02198924 | Dec 2014 → Nov 2016 | — | Peking Union Medical College Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02389465 | Aug 2014 → Jul 2022 | depressive disorder | University of Pennsylvania | Completed | No outcome recorded |
| Phase 4 | NCT01838044 | Oct 2013 → May 2015 | neuropathy, painful | Viatris Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT02850211 | Sep 2011 → Nov 2015 | rotator cuff syndrome | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01479829 | Mar 2011 → Dec 2017 | bipolar depression | Loyola University | Completed | No outcome recorded |
| Phase 4 | NCT00894790 | Nov 2009 → Jan 2010 | — | Viatris Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT00994461 | Nov 2009 → Apr 2010 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00807846 | Sep 2009 → Dec 2012 | juvenile idiopathic arthritis | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01111591 | Nov 2008 → Jun 2017 | bile duct cancer, malignant pancreatic neoplasm | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00624559 | Feb 2008 → Jan 2009 | hypertensive disorder | University of Delaware | Completed | No outcome recorded |
| Phase 4 | NCT00778193 | Oct 2007 → Mar 2008 | peptic ulcer disease | Research Associates of New York, LLP | Completed | No outcome recorded |
| Phase 4 | NCT00447759 | Jun 2007 → Aug 2015 | osteoarthritis, rheumatoid arthritis | University of Dundee | Completed | No outcome recorded |
| Phase 4 | NCT00446797 | May 2007 → Apr 2008 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00500279 | Nov 2006 → Oct 2009 | coronary restenosis | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00359151 | Nov 2006 → Jul 2007 | osteoarthritis | Viatris Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT00346216 | Oct 2006 → Apr 2016 | rheumatoid arthritis | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00373685 | Oct 2006 → Nov 2010 | osteoarthritis | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00290901 | Mar → Dec 2006 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00304317 | Mar 2006 → Aug 2008 | ureterolithiasis | University of Minnesota | Withdrawn | No outcome recorded |
| Phase 4 | NCT00141102 | Oct 2005 → May 2009 | osteoarthritis, rheumatoid arthritis | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00137033 | Sep 2004 → Jul 2005 | peptic ulcer disease | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00194090 | Jun 2004 → Sep 2005 | osteoarthritis, knee | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00643799 | Mar 2004 → Jan 2005 | osteoarthritis, knee | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00633438 | Jan → Jun 2004 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00640627 | Dec 2003 → Sep 2004 | osteoarthritis, knee | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00638807 | Dec 2003 → Jul 2004 | osteoarthritis, knee | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00640432 | Oct 2003 → Oct 2004 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00640809 | Oct 2003 → Apr 2004 | inflammatory bowel disease | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00174317 | Aug 2003 → Feb 2005 | osteoarthritis, hip | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00565500 | Apr 2003 → Apr 2005 | ischemic disease, osteoarthritis | University of Chieti | Completed | No outcome recorded |
| Phase 4 | NCT00633386 | Feb → Aug 2003 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00630929 | Jan 2003 → Feb 2004 | osteoarthritis, knee | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00620867 | Oct 2002 → Mar 2003 | osteoarthritis, knee | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00471341 | Jul 2002 → Dec 2004 | coronary artery disorder | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT00473980 | Dec 1998 → May 2007 | colorectal cancer | Göteborg University | Completed | No outcome recorded |
| Phase 4 | NCT00261586 | ? → Mar 2004 | — | Johnson & Johnson Consumer and Personal Products Worldwide | Completed | No outcome recorded |
| Phase 4 | NCT00664690 | — | — | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Withdrawn | No outcome recorded |
| Phase not applicable29 trials | ||||||
| — | NCT07673549 | Aug 2026 → Dec 2027 expected | trigeminal neuralgia | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07154433 | Sep 2025 → May 2026 | osteochondritis dissecans | Second Affiliated Hospital, School of Medicine, Zhejiang University | Completed | No outcome recorded |
| — | NCT06722534 | Feb 2025 → Jan 2029 expected | Peutz-Jeghers syndrome, intestinal polyp | Air Force Military Medical University, China | Recruiting | No outcome recorded |
| — | NCT05994287 | Jan 2021 → Jan 2022 | — | Federal State Budgetary Organization, Federal Center for Traumatology, Orthopedics and Arthroplasty | Completed | No outcome recorded |
| — | NCT03499743 | Apr → Sep 2018 | — | Cairo University | Completed | No outcome recorded |
| — | NCT03351439 | Apr 2018 → Sep 2021 | chronic pain syndrome | Western University, Canada | Completed | No outcome recorded |
| — | NCT03339544 | Dec 2017 → Dec 2018 | pulpitis | Cairo University | Unknown | No outcome recorded |
| — | NCT02790203 | Jun 2016 → Dec 2018 | ileus | Sheba Medical Center | Unknown | No outcome recorded |
| — | NCT02413203 | Mar → Nov 2015 | — | University of Pennsylvania | Completed | No outcome recorded |
| — | NCT02255006 | May → Oct 2014 | — | Kyunghee University Medical Center | Unknown | No outcome recorded |
| — | NCT01800799 | Feb 2013 → Dec 2014 | urinary tract infection | Buddhist Tzu Chi General Hospital | Completed | No outcome recorded |
| — | NCT02779166 | Aug 2012 → Jan 2016 | — | Northwestern University | Completed | No outcome recorded |
| — | NCT01631669 | May 2012 → Jun 2015 | myositis ossificans | Walter Reed National Military Medical Center | Unknown | No outcome recorded |
| — | NCT01284504 | Jan → May 2011 | colon carcinoma | Stanford University | Terminated | No outcome recorded |
| — | NCT01323595 | Jan 2011 → Dec 2012 | — | Weill Medical College of Cornell University | Terminated | No outcome recorded |
| — | NCT01129245 | Sep 2009 → Sep 2011 | anovulation | Oregon Health and Science University | Completed | No outcome recorded |
| — | NCT00614406 | Jan → Aug 2008 | — | Oregon Health and Science University | Completed | No outcome recorded |
| — | NCT00526214 | Oct 2007 → May 2009 | intracerebral hemorrhage | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT00686140 | Jun 2006 → Dec 2007 | schizophrenia | Beijing HuiLongGuan Hospital | Completed | No outcome recorded |
| — | NCT00084578 | Mar 2004 → Apr 2006 | urinary bladder cancer | Fox Chase Cancer Center | Withdrawn | No outcome recorded |
| — | NCT00596219 | Dec 2003 → Oct 2006 | squamous cell carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| — | NCT00065559 | Apr 2003 → Dec 2004 | diabetic kidney disease | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Terminated | No outcome recorded |
| — | NCT01762891 | Mar 2003 → Jul 2006 | antiphospholipid syndrome | Hospital Universitario Pedro Ernesto | Completed | No outcome recorded |
| — | NCT00608595 | Jul 2002 → May 2004 | colorectal cancer | Vanderbilt-Ingram Cancer Center | Terminated | No outcome recorded |
| — | NCT00084370 | Jun 2002 → Mar 2005 | BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, ovarian carcinoma | University of Alabama at Birmingham | Withdrawn | No outcome recorded |
| — | NCT00653250 | Dec 2000 → Mar 2006 | lung carcinoma | Vanderbilt-Ingram Cancer Center | Completed | No outcome recorded |
| — | NCT00065169 | Nov 2000 → Nov 2005 | Alzheimer disease | University of California, Los Angeles | Completed | No outcome recorded |
| — | NCT00533247 | — | — | Zanbilowicz, Adam, DPM MS | Unknown | No outcome recorded |
| — | NCT00093678 | — | cancer of unknown primary site, cutaneous melanoma, hypoproteinemia, hypercatabolic, lymphoma +2 | Eastern Cooperative Oncology Group | Withdrawn | No outcome recorded |
Also used as a comparator or background therapy in 187 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT03590821 Background | Dec 2027 → Jan 2028 expected | — | University of Pennsylvania | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06451783 Comparator | May 2024 → Apr 2025 | osteoarthritis, knee | Xuhui Central Hospital, Shanghai | Unknown | No outcome recorded |
| Phase 0 | NCT05852093 Comparator | Jun 2023 → Jun 2026 overdue | rotator cuff syndrome | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 126 trials | ||||||
| Phase 1 | NCT07632599 Background | Jul 2026 → Jun 2027 expected | ankylosing spondylitis | Eighth Affiliated Hospital, Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07351968 Comparator | Mar → Aug 2026 overdue | osteoarthritis, knee | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07171034 Comparator | Sep 2025 → May 2026 overdue | — | Hunan Kelun Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07559682 Comparator | May → Aug 2025 overdue | — | Sharif Medical Research Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05436678 Comparator | Jul → Aug 2022 | — | NeuroSense Therapeutics Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05555823 Comparator | Jun 2022 → Jul 2023 | — | Atriva Therapeutics GmbH | Completed | No outcome recorded |
| Phase 1 | NCT05232461 Comparator | Apr 2022 | — | NeuroSense Therapeutics Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05237297 Comparator | Feb → Jul 2022 | — | Il-Yang Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04639804 Comparator | Jun → Jul 2020 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03643744 Comparator | Apr 2019 → Mar 2023 | actinic keratosis | Wright State University | Terminated | No outcome recorded |
| Phase 1 | NCT02839694 Comparator | Jul 2016 → Apr 2017 | germ cell tumor, melanoma, metastatic neoplasm, sarcoma | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 1 | NCT02179645 Comparator | May → Dec 2014 | — | Glenmark Pharmaceuticals Ltd. India | Completed | No outcome recorded |
| Phase 1 | NCT01968070 Comparator | Oct 2013 → Apr 2014 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01849055 Comparator | May → Dec 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01632566 Comparator | Jun 2012 → Apr 2013 | — | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 1 | NCT01632579 Comparator | Jun → Sep 2012 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01449630 Comparator | Oct 2011 → Apr 2012 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02695745 Comparator | Sep 2011 → Jan 2012 | — | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 1 | NCT01341496 Background | Apr 2011 → May 2016 | epithelial neoplasm, melanoma, pleural cancer, sarcoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT01313429 Background | Mar 2011 → Feb 2020 | epithelial neoplasm, melanoma, pleural cancer, sarcoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT01304069 Comparator | Jan → Jul 2011 | — | Turku University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01143545 Background | Dec 2010 → Feb 2015 | esophageal cancer, lung cancer, malignant pleural mesothelioma, sarcoma +1 | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT00925106 Comparator | Jul → Aug 2009 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00813241 Comparator | Jan → Mar 2009 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00780325 Comparator | Oct 2008 → Jul 2013 | — | University of Pennsylvania | Terminated | No outcome recorded |
| Phase 1 | NCT00081848 Background | Apr 2004 → Aug 2007 | liver and intrahepatic bile duct neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT07246278 Comparator | Nov 2025 → Nov 2026 expected | Parkinson disease | Tanta University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04767841 Background | Feb 2021 → Jun 2024 | osteoarthritis, knee | Sadat City University | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT05547659 Comparator | Jan 2019 → Apr 2020 | — | October 6 University | Completed | No outcome recorded |
| Phase 1/2 | NCT02432378 Background | Sep 2015 → Jun 2025 | ovarian cancer | Roswell Park Cancer Institute | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00197912 Background | Sep 2004 → Apr 2010 | melanoma | Herlev Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT00057980 Background | Oct 2002 → Feb 2007 | liver cancer | Northwestern University | Completed | No outcome recorded |
| Phase 233 trials | ||||||
| Phase 2 | NCT07634094 Background | Aug 2026 → Aug 2028 expected | ovarian cancer | Kalinski, Pawel, MD, PhD | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07543796 Comparator | Mar → Jun 2026 overdue | — | Beijing Tide Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT07154316 Background | Aug 2025 → Aug 2028 expected | colorectal cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT01344200 Comparator | Jan 2024 → Jan 2026 overdue | — | Children's Hospital of Eastern Ontario | Recruiting | No outcome recorded |
| Phase 2 | NCT06185543 Comparator | Nov 2023 → Sep 2025 | Alzheimer disease | NeuroSense Therapeutics Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT05962957 Comparator | Aug 2023 → Sep 2024 | Parkinson disease | Mostafa Bahaa | Completed | No outcome recorded |
| Phase 2 | NCT05637086 Comparator | Dec 2022 → Dec 2026 expected | epilepsy | Mostafa Bahaa | Recruiting | No outcome recorded |
| Phase 2 | NCT05357950 Comparator | May 2022 → Nov 2023 | amyotrophic lateral sclerosis | NeuroSense Therapeutics Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT03885596 Background | Mar → Jul 2019 | — | Concentric Analgesics | Completed | No outcome recorded |
| Phase 2 | NCT03625050 Comparator | Nov 2018 → Dec 2020 | — | Gachon University Gil Oriental Medical Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03850587 Comparator | Aug 2018 → May 2020 | osteoarthritis, knee | Yooyoung Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT03084536 Comparator | Jun 2017 → Feb 2021 | female breast carcinoma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT02641314 Background | Dec 2016 → Jun 2023 | neuroblastoma | University of Cologne | Completed | No outcome recorded |
| Phase 2 | NCT02759198 Comparator | May 2016 → May 2017 | osteoarthritis, knee | Yuhan Corporation | Completed | No outcome recorded |
| Phase 2 | NCT03523832 Comparator | Jul 2015 → Dec 2016 | — | Faculty of Medicine, University of Indonesia | Completed | No outcome recorded |
| Phase 2 | NCT02307305 Background | Aug 2014 → Dec 2016 | neuropathy, painful | Hanyang University Seoul Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02192190 Comparator | Jul 2014 → Apr 2015 | osteoarthritis, knee | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 2 | NCT02071303 Comparator | May → Nov 2014 | — | Cairo University | Completed | No outcome recorded |
| Phase 2 | NCT01872910 Comparator | Jun → Oct 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT01341405 Comparator | Apr → Dec 2011 | osteoarthritis | CrystalGenomics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02456363 Background | Nov 2009 → Oct 2019 | ankylosing spondylitis | Chung Shan Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT00985439 Comparator | Sep → Dec 2009 | — | Iroko Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 2 | NCT00964431 Comparator | Aug → Dec 2009 | — | Iroko Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 2 | NCT00571701 Comparator | Feb 2008 → Jan 2015 | recurrent respiratory papillomatosis | Northwell Health | Completed | No outcome recorded |
| Phase 2 | NCT00583453 Comparator | Oct 2007 → Dec 2013 | tonsillitis | University of Iowa | Completed | No outcome recorded |
| Phase 2 | NCT00424294 Comparator | Jun 2006 → Dec 2007 | rheumatoid arthritis | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT00597415 Comparator | Dec 2004 → Feb 2008 | osteoarthritis, knee | University Hospitals Cleveland Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT00602901 Background | Jul 2004 → Oct 2006 | chronic pain syndrome, subacute bursitis | Palmer College of Chiropractic | Completed | No outcome recorded |
| Phase 2 | NCT00068770 Comparator | Oct 2003 → May 2005 | central nervous system neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 2 | NCT00504660 Comparator | Sep 2003 → Aug 2010 | brain cancer, glioblastoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00291694 Comparator | Apr 2003 → Dec 2009 | breast cancer | Carol Fabian, MD | Completed | No outcome recorded |
| Phase 2 | NCT00582660 Comparator | Dec 2001 → Jun 2008 | colorectal adenoma, colorectal carcinoma | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT02840162 Comparator | May 2001 → Jan 2005 | prostate adenocarcinoma | OHSU Knight Cancer Institute | Terminated | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT05638893 Background | Feb 2021 → Mar 2022 | osteoarthritis, knee | Tanta University | Completed | No outcome recorded |
| Phase 2/3 | NCT04562610 Comparator | Nov 2020 → Oct 2024 | vertebral column disorder | University of California, Davis | Completed | No outcome recorded |
| Phase 2/3 | NCT04342065 Comparator | Jan 2019 → Jan 2020 | — | South Egypt Cancer Institute | Completed | No outcome recorded |
| Phase 345 trials | ||||||
| Phase 3 | NCT07414706 Background | Mar 2026 → Jun 2028 expected | local anesthetic poisoning | Centre Hospitalier Universitaire, Amiens | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06545526 Comparator | Aug 2024 → Jun 2026 overdue | classic familial adenomatous polyposis | Yonsei University | Recruiting | No outcome recorded |
| Phase 3 | NCT05965492 Background | Jun 2024 → Jun 2025 | spinal cord disorder | University of Miami | Withdrawn | No outcome recorded |
| Phase 3 | NCT06231758 Comparator | Jan 2024 → Nov 2026 expected | osteoarthritis, knee | Mostafa Bahaa | Recruiting | No outcome recorded |
| Phase 3 | NCT05644301 Comparator | Sep 2023 → Sep 2026 expected | major depressive disorder | University of Antwerp | Recruiting | No outcome recorded |
| Phase 3 | NCT05327751 Comparator | Apr 2022 → Apr 2024 | colorectal cancer, hand-foot syndrome | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT05324163 Comparator | Sep 2021 → Feb 2023 | osteoarthritis, knee | Jiangsu XinChen-Techfields Pharma Co., LTD. | Completed | No outcome recorded |
| Phase 3 | NCT04788654 Background | Mar → Jul 2021 | — | Gangnam Severance Hospital | Completed | No outcome recorded |
| Phase 3 | NCT05930080 Comparator | Jan 2021 → May 2022 | osteoarthritis, knee | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03710876 Comparator | Jan 2019 → Mar 2024 | malignant pleural mesothelioma | Ferring Ventures Limited | Completed | No outcome recorded |
| Phase 3 | NCT03031938 Background | Nov 2017 → Jun 2020 | osteoarthritis | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT03184493 Comparator | Jun 2017 → Dec 2020 | liver cancer | Guangxi Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT03108482 Comparator | Mar → Nov 2017 | — | Esteve Pharmaceuticals, S.A. | Completed | No outcome recorded |
| Phase 3 | NCT02982161 Comparator | Dec 2016 → Jan 2018 | — | Mundipharma Research GmbH & Co KG | Completed | No outcome recorded |
| Phase 3 | NCT02674386 Background | Aug 2016 → Jul 2019 | osteoarthritis | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT02736071 Comparator | Jun 2016 → Apr 2017 | — | Cairo University | Unknown | No outcome recorded |
| Phase 3 | NCT02736019 Comparator | Jun 2016 → Apr 2017 | — | Cairo University | Unknown | No outcome recorded |
| Phase 3 | NCT02725411 Comparator | May 2016 → Jun 2019 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT02688400 Comparator | May 2016 → Jun 2018 | osteoarthritis, knee | TRB Chemedica International SA | Completed | No outcome recorded |
| Phase 3 | NCT02528188 Comparator | Jul 2015 → Oct 2018 | chronic pain syndrome, osteoarthritis, hip, osteoarthritis, knee | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT02301234 Comparator | Mar 2015 → Sep 2016 | osteoarthritis | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02079727 Comparator | Jun 2014 → Oct 2015 | osteoarthritis, knee | IBSA Institut Biochimique SA | Completed | No outcome recorded |
| Phase 3 | NCT01765296 Comparator | Mar → Dec 2013 | osteoarthritis, hip, osteoarthritis, knee | CrystalGenomics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01768520 Comparator | Jul 2012 → Oct 2014 | osteoarthritis, knee | Hanlim Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01554163 Comparator | Mar 2012 → Mar 2013 | osteoarthritis, knee | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT01543685 Comparator | Feb → Jun 2012 | — | Iroko Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 3 | NCT01462435 Comparator | Oct 2011 → Feb 2012 | — | Iroko Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 3 | NCT01354145 Comparator | Jun 2011 → Sep 2014 | osteoarthritis, knee | Bioiberica | Completed | No outcome recorded |
| Phase 3 | NCT01781702 Comparator | Oct 2010 → Oct 2011 | rheumatoid arthritis | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01576419 Comparator | Jan 2010 → Mar 2011 | osteoarthritis, knee | PMG Pharm Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT01535417 Comparator | May → Dec 2009 | osteoarthritis, knee | Green Cross Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00716547 Comparator | May 2008 → Mar 2009 | osteoarthritis, knee | IDEA AG | Completed | No outcome recorded |
| Phase 3 | NCT00665431 Comparator | Apr → Dec 2008 | osteoarthritis | POZEN | Completed | No outcome recorded |
| Phase 3 | NCT00664560 Comparator | Apr → Dec 2008 | osteoarthritis | POZEN | Completed | No outcome recorded |
| Phase 3 | NCT00581685 Comparator | Jan 2008 → Jun 2010 | osteoarthritis | Sunnybrook Health Sciences Centre | Completed | No outcome recorded |
| Phase 3 | NCT00546507 Comparator | Oct 2007 → Oct 2008 | osteoarthritis | Mika Pharma GmbH | Completed | No outcome recorded |
| Phase 3 | NCT00546832 Comparator | Oct 2007 → Oct 2008 | osteoarthritis, knee | Mika Pharma GmbH | Completed | No outcome recorded |
| Phase 3 | NCT00300729 Comparator | May 2006 → May 2010 | non-small cell lung carcinoma | University Hospital, Linkoeping | Unknown | No outcome recorded |
| Phase 3 | NCT00603759 Comparator | Apr 2006 → Aug 2007 | head and neck cancer | Tehran University of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT00153660 Comparator | Jun 2005 → Nov 2014 | arthritic joint disease, cerebrovascular disorder | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 3 | NCT00087256 Comparator | Jul 2004 → Apr 2006 | colorectal cancer | NSABP Foundation Inc | Terminated | No outcome recorded |
| Phase 3 | NCT00175032 Comparator | Jul 2003 → Jul 2004 | osteoarthritis, peptic ulcer disease | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00365313 Background | Aug 2002 → Jun 2005 | arthritic joint disease, ulcer disease | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 3 | NCT00153673 Comparator | Feb 2001 → Dec 2016 | arthritic joint disease, gastric ulcer | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 3 | NCT00141193 Comparator | Feb 2001 → May 2007 | colorectal adenoma | Pfizer | Completed | No outcome recorded |
| Phase 447 trials | ||||||
| Phase 4 | NCT06113211 Background | Oct 2024 → Sep 2026 expected | disease of bone structure, substance-related disorder | Henry Ford Health System | Recruiting | No outcome recorded |
| Phase 4 | NCT06245109 Comparator | Feb 2024 → Mar 2028 expected | osteoarthritis, knee | Northwestern University | Recruiting | No outcome recorded |
| Phase 4 | NCT05974501 Background | Sep 2023 → Jan 2024 | osteoarthritis, knee | University of Miami | Completed | No outcome recorded |
| Phase 4 | NCT05488847 Background | Jun 2022 → Dec 2024 overdue | arthropathy | Henry Ford Health System | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06336993 Comparator | Jan 2022 → Jun 2023 | — | Zhejiang Provincial Tongde Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04765644 Comparator | Jun 2021 → Jan 2022 | — | Imperial College London | Completed | No outcome recorded |
| Phase 4 | NCT04790812 Comparator | Apr 2021 → Mar 2023 | — | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT04314505 Background | Mar → Jun 2020 | — | Taipei Veterans General Hospital, Taiwan | Unknown | No outcome recorded |
| Phase 4 | NCT04020588 Comparator | Feb 2019 → Jun 2020 | schizophrenia | Hospital Psiquiatrico Infantil Dr. Juan N. Navarro, Mexico | Unknown | No outcome recorded |
| Phase 4 | NCT03694873 Comparator | Oct → Dec 2018 | — | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT03699293 Comparator | Sep 2018 → Dec 2022 | cardiovascular disorder, rheumatoid arthritis | Platelet and Thrombosis Research, LLC | Terminated | No outcome recorded |
| Phase 4 | NCT03645187 Comparator | Aug 2018 → Aug 2025 | colon carcinoma | Tanta University | Unknown | No outcome recorded |
| Phase 4 | NCT03464552 Comparator | Apr 2018 → Jun 2019 | — | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT03472469 Comparator | Apr 2018 → Jul 2019 | — | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT03473665 Comparator | Mar 2018 → Aug 2019 | ankylosing spondylitis | Columbia University | Terminated | No outcome recorded |
| Phase 4 | NCT03068260 Comparator | Mar → Dec 2017 | — | Zealand University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02987920 Background | Jan 2017 → Jan 2018 | — | University of Southern California | Terminated | No outcome recorded |
| Phase 4 | NCT03067194 Comparator | Dec 2016 → Jul 2017 | osteoarthritis, hand | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 4 | NCT03540030 Comparator | Sep 2016 → Mar 2019 | avascular necrosis, osteoarthritis, rotator cuff syndrome, substance-related disorder | OrthoCarolina Research Institute, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT02758782 Comparator | Sep 2016 → Jan 2021 | ankylosing spondylitis | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 4 | NCT02827487 Comparator | Jul 2016 → Jul 2020 | — | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT02703259 Comparator | Jun 2016 → Jul 2017 | — | Christiana Care Health Services | Completed | No outcome recorded |
| Phase 4 | NCT02638896 Background | Jan 2016 → Feb 2017 | ankylosing spondylitis | Zhixiang Huang | Unknown | No outcome recorded |
| Phase 4 | NCT02643394 Comparator | Aug 2015 → Sep 2016 | — | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02351934 Background | Feb 2015 → Apr 2016 | large intestine disorder | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT02355236 Comparator | Feb → Dec 2015 | osteoarthritis | Severance Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01934933 Comparator | Sep 2014 → Sep 2015 | ankylosing spondylitis | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 4 | NCT02110719 Comparator | Mar 2014 → Jul 2015 | constipation disorder | Hartford Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03305068 Comparator | Feb 2014 → Mar 2018 | — | St. Louis Joint Replacement Institute | Unknown | No outcome recorded |
| Phase 4 | NCT01837433 Background | Mar 2013 → Dec 2014 | subacute thyroiditis | Xinqiao Hospital of Chongqing | Completed | No outcome recorded |
| Phase 4 | NCT01555073 Comparator | Oct 2011 → Aug 2013 | leiomyoma | Northwestern University | Terminated | No outcome recorded |
| Phase 4 | NCT01425853 Comparator | Sep 2011 → Apr 2013 | osteoarthritis, knee | Bioiberica | Completed | No outcome recorded |
| Phase 4 | NCT01860833 Comparator | Apr 2010 → Aug 2011 | osteoarthritis, knee | University of Catanzaro | Completed | No outcome recorded |
| Phase 4 | NCT01374269 Comparator | Jun 2009 → Oct 2011 | — | Grupo Rehabilitacion en Salud | Completed | No outcome recorded |
| Phase 4 | NCT01344213 Comparator | Jul 2008 → Oct 2009 | — | Chulalongkorn University | Completed | No outcome recorded |
| Phase 4 | NCT00687388 Comparator | May 2008 → Mar 2012 | benign prostatic hyperplasia | Samsung Medical Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT00484718 Comparator | Jan 2008 → Jun 2009 | osteoarthritis, knee | Pfizer | Terminated | No outcome recorded |
| Phase 4 | NCT01728246 Background | Oct 2007 → May 2008 | osteoarthritis | Janssen Pharmaceutica | Completed | No outcome recorded |
| Phase 4 | NCT00520338 Comparator | Aug 2007 → Dec 2009 | — | Mahidol University | Completed | No outcome recorded |
| Phase 4 | NCT00598234 Comparator | Sep 2006 → Aug 2009 | osteoarthritis | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00139776 Comparator | Jul 2005 → Feb 2008 | osteoarthritis, hip, osteoarthritis, knee | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00882388 Comparator | Mar → Jun 2005 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00292721 Comparator | Aug 2004 → Oct 2008 | coronary atherosclerosis | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00904397 Comparator | Jul → Nov 2004 | chronic pain syndrome | Endo USA Inc., a Keenova Therapeutics Company | Terminated | No outcome recorded |
| Phase 4 | NCT00904605 Comparator | Jun → Nov 2004 | osteoarthritis, knee | Endo USA Inc., a Keenova Therapeutics Company | Terminated | No outcome recorded |
| Phase 4 | NCT00177866 Comparator | Dec 2003 → Jun 2010 | Crohn disease | University of Pittsburgh | Terminated | No outcome recorded |
| Phase 4 | NCT02528201 Comparator | Sep 2002 → Nov 2004 | ankylosing spondylitis | Pfizer | Completed | No outcome recorded |
| Phase not applicable24 trials | ||||||
| — | NCT07353372 Background | Jan 2026 → Sep 2028 expected | — | Xuanwu Hospital, Beijing | Not yet recruiting | No outcome recorded |
| — | NCT07032883 Background | Jun 2025 → Feb 2026 overdue | female breast carcinoma | Cairo University | Not yet recruiting | No outcome recorded |
| — | NCT06344403 Background | Jun 2025 → Oct 2026 expected | herpes zoster | Beijing Tiantan Hospital | Active not recruiting | No outcome recorded |
| — | NCT06602167 Background | Oct 2024 → Jul 2027 expected | breast cancer, digestive system cancer, hand-foot syndrome | Affiliated Hospital of Qinghai University | Recruiting | No outcome recorded |
| — | NCT06328153 Comparator | Mar 2024 → Jan 2026 | osteoarthritis, knee | Guangdong Provincial Hospital of Traditional Chinese Medicine | Unknown | No outcome recorded |
| — | NCT06009900 Comparator | Sep 2023 | chronic pain syndrome | Tongji Hospital | Unknown | No outcome recorded |
| — | NCT05911126 Comparator | Jun → Oct 2023 | — | Cairo University | Unknown | No outcome recorded |
| — | NCT06420388 Background | May 2023 → Jul 2024 | — | E-DA Hospital | Unknown | No outcome recorded |
| — | NCT05765747 Comparator | Apr → Dec 2023 | — | Peking University Third Hospital | Unknown | No outcome recorded |
| — | NCT04718649 Background | Jan 2021 → Dec 2022 | osteoarthritis | The Catholic University of Korea | Unknown | No outcome recorded |
| — | NCT04505657 Comparator | Sep 2020 → Jun 2021 | uterine inflammatory disease | Aswan University Hospital | Completed | No outcome recorded |
| — | NCT03563690 Comparator | Jul 2018 → Oct 2021 | osteoarthritis, knee | Zhejiang Chinese Medical University | Completed | No outcome recorded |
| — | NCT03337607 Comparator | Nov 2017 → Apr 2019 | — | First Affiliated Hospital of Zhejiang University | Completed | No outcome recorded |
| — | NCT03391570 Comparator | Oct 2017 → Oct 2019 | female reproductive system disorder | Seoul National University Hospital | Unknown | No outcome recorded |
| — | NCT02993029 Comparator | Sep 2017 → Dec 2027 expected | — | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| — | NCT02600247 Background | Nov 2015 → Nov 2016 | osteoarthritis | The Catholic University of Korea | Unknown | No outcome recorded |
| — | NCT02260336 Comparator | Oct 2014 → Sep 2018 | rheumatic disorder | Chengdu PLA General Hospital | Unknown | No outcome recorded |
| — | NCT02208583 Comparator | Jun 2014 → Dec 2016 | hormone-resistant prostate carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| — | NCT02408146 Background | Jan 2014 → Jul 2015 | neuropathy, painful | First Affiliated Hospital of Harbin Medical University | Unknown | No outcome recorded |
| — | NCT01943435 Comparator | Nov 2013 → Jun 2016 | lumbar spinal stenosis | Michael Schneider, DC, PhD | Completed | No outcome recorded |
| — | NCT01638962 Comparator | Aug 2012 → Aug 2015 | osteoarthritis, knee | University of Southern Denmark | Completed | No outcome recorded |
| — | NCT01623921 Comparator | Aug 2012 → Aug 2013 | acute respiratory distress syndrome | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| — | NCT01709656 Background | Mar 2012 → Dec 2014 | ankylosing spondylitis | Sun Yat-sen University | Completed | No outcome recorded |
| — | NCT01186887 Comparator | Feb 2009 → Apr 2013 | — | Ottawa Hospital Research Institute | Completed | No outcome recorded |
Press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2016-11-13 | Pfizer | Landmark Study Demonstrates Pfizer’s Celebrex (Celecoxib)Has Similar Cardiovascular Risk As Compared To Prescription Doses Of Ibuprofen and Naproxen pfizer.com ↗ |
| 2014-12-10 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Launch of First Generic Celebrex® Capsules in the United States tevapharm.com ↗ |
| 2014-05-30 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Receives Favorable Court Decision Regarding Generic Celebrex® Capsules; Teva Should Receive Sole Exclusivity for Generic Celebrex® Capsules tevapharm.com ↗ |
| 2014-04-17 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Settles Patent Litigation with Pfizer on Celebrex® tevapharm.com ↗ |
| 2007-03-21 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Provides Update On Generic CELEBREX® Litigation tevapharm.com ↗ |
Evidence & citations 28 cited values
Every value below carries the sentence it was read from. 590 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CELECOXIB | “The study investigates the tolerance and the efficacy of a new combination of five drugs consisting of propranolol (antiangiogenetic, anti-neuroblastic), Celecoxib (modulating...” NCT02641314 ↗552“Participants with v-akt murine thymoma viral oncogene homologue 1 (AKT1) gene mutations will receive a drug called Celecoxib, which inhibits a protein called v-akt murine...” NCT02208583 ↗ “Purpose: pharmacokinetic interactions and safety of AD-2111 and AD-2112 in healthy adult volunteers Condition or disease : Pain Intervention/treatment Drug : AD-2111(Celecoxib...” NCT04375865 ↗ “Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, phase...” PMID 25403311 ↗ Nov 2014 “A Six Week Double-Blind, Randomized, Multicenter Comparison Study of the Analgesic Effectiveness of Celecoxib 200 mg BID Compared to Tramadol Hydrochloride 50 mg QID in...” NCT00290901 ↗ “Subjects in the oral administration group will receive the following pre-emptive analgesic drugs, acetaminophen 1,000mg, Celecoxib 200mg and gabapentin 600mg via the oral route...” NCT04562610 ↗ “PrimeC is a fixed-dose oral combination of celecoxib and ciprofloxacin designed to target ALS-related mechanisms, including neuroinflammation, iron homeostasis, and...” PMID 41837970 ↗ May 2026 “Nonsteroidal anti-inflammatory drug celecoxib (200 mg on request, up to two times daily)27 and tramadol (100 mg on request, up to 400mg daily) will be available for as-needed analgesia.” NCT06344403 ↗ “PK101, a fixed-dose combination (FDC) comprising PG201, a 12-herb extract used in OA treatment in traditional East Asian medicine, and celecoxib, a selective cyclooxygenase-2 inhibitor” PMID 39560548 ↗ Nov 2024 “Immediately after surgery, patients will receive oral acetaminophen 500 mg plus celecoxib 400 mg. Thereafter, celecoxib 200 mg BID and acetaminophen 500 mg Q6H will be administered.” NCT07154433 ↗ “Drug: Celebrex (Celebrex, Capsules, Pfizer Pharmaceuticals Ltd), which will be applied 1 time daily( taken 0.2g one time orally ) Time of treatment :4 weeks Other Name: celecoxib” NCT03563690 ↗ “Celecoxib 6mg/kg (maximum 400mg) by mouth once then 3 mg/kg (maximum 200mg) every 12 hours around the clock for 2 days, then as needed for pain thereafter (40 doses)” NCT06671002 ↗ “A Phase I Trial of Postoperative Radiation With Dose-Escalation of A Cox-2 Inhibitor, Celebrex™ (CELECOXIB) in Patients With Soft Tissue Sarcoma of the Extremity” NCT00450736 ↗ “Disitamab Vedotin (2mg/kg, q2w), Tislelizumab (2mg/kg, q2w) combined with low-dose capecitabine 0.5g bid chemotherapy and the COX2 inhibitor celecoxib 200mg bid” NCT05578287 ↗ “Effectiveness and Safety of Celecoxib (Celebrex 200 mg) Combined With Joins in the Treatment of Degenerative Knee Osteoarthritis: a Randomized Controlled Trial” NCT04718649 ↗ “Participants in tramadol/APAP group will receive celecoxib 200 milligram (mg) and fixed dose combination of tramadol (37.5 mg)/APAP (325 mg) as add on therapy” NCT01728246 ↗ “500 mg metformin-HCL XR plus 100 mg celecoxib once-a-day in the morning and 160 mg valsartan 6 hours later once-a-day in the afternoon for 26 weeks.” NCT03686657 ↗ “The second group was treated for 10 days with NSAIDs (naproxen 500 mg/d or celecoxib 200 mg/d) according to the indications and contraindications.” NCT01374269 ↗ “The purpose of the study is to find out whether the drug celecoxib has beneficial effects on people with pre-cancerous lesions of the pancreas.” NCT00198081 ↗ “Drug (Celecoxib as 200mg twice daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery” NCT02748707 ↗ “2 tablets of PrimeC administered twice daily (4 tablets a day), total daily dose of 1360 mg ciprofloxacin and 136 mg celecoxib orally.” NCT06185543 ↗ “DFN-15, a novel oral liquid formulation of celecoxib, is being developed for the acute treatment of migraine with or without aura.” PMID 28748412 ↗ Oct 2017 “Daily oral Celecoxib (100 mg BID for patients \< 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients \> 50 kg)” NCT01858571 ↗ “Celecoxib: 200 mg, Oral, two times per day for five days with a visually matching sequential placebo in between of two doses.” NCT01280006 ↗ “Prednisone 1 week 30mg/day and Celecoxib 400mg in first day, and then 200mg bid in the remaining next week, total 2 weeks.” NCT01837433 ↗ “The efficacy and safety of the association of celecoxib \[a selective cyclooxygenase-2 (COX-2) inhibitor\] and pregabalin” NCT03584074 ↗ “The study drugs are a combination of celecoxib (Celebrex®), Interferon-α2b (IFN), and rintatolimod (Ampligen®), or CKM.” NCT02615574 ↗ “N-acetylcysteine and celecoxib start day of admission (prior to conditioning regimen) and continue through day +100” NCT02171104 ↗ “All patients received oral paracetamol 500mg, 4 times a day and oral celecoxib 200mg, 2 times a day after surgery.” NCT04314505 ↗ “Patients will be randomized to receive celecoxib suspension 6 mg/kg one hour prior to their scheduled surgery.” NCT00849966 ↗ “IMP would have been either placebo, tanezumab, celecoxib, naproxen or diclofenac administered in parent study.” NCT02674386 ↗ “IMP would have been either placebo, tanezumab, celecoxib, naproxen, diclofenac, administered in parent study” NCT03031938 ↗ “Orally administered NSAID (naproxen 500 mg, celecoxib 100 mg or diclofenac 75 mg) twice daily for 56 weeks” NCT02528188 ↗ “Celebrex(celecoxib, pfizer) 200mg twice daily is administered for 5 days before FMD measurement.” NCT02255006 ↗ “Effect of Celecoxib and Etoricoxib on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol” NCT01304069 ↗ “* Celecoxib 400 mg by mouth once then 200 mg every twelve hours as needed for pain (10 doses)” NCT05722002 ↗ “Acetaminophen 975 mg Celecoxib 200 mg Gabapentin 300 mg Oxycodone 10 mg Extended Release” NCT04522206 ↗ “starts thalidomide (50) 4# per day and celecoxib (Celebrex)(200) 2# bid for three weeks” NCT00934739 ↗ “celecoxib (CEL) (200 mg) given once daily versus placebo in knee osteoarthritis (OA).” PMID 26313454 ↗ Aug 2015 “Celecoxib/placebo treatment will commence on the same day as chemotherapy treatment” NCT00101686 ↗ “1000mg oral acetaminophen + 400mg oral celecoxib given within one hour of incision” NCT02643394 ↗ “Postoperative analgesia regimen: Paracetamol 1 g ×4/day; Celecoxib 100 mg ×2/day” NCT07414706 ↗ “Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks” NCT00809354 ↗ “One dose of Pregabalin 100mg and Celecoxib 400mg along with interscalene block” NCT07076069 ↗ “then followed by oral celecoxib 200 mg once or twice daily till pain subsides.” NCT07032883 ↗ “receive additional celecoxib 200mg bid every days during chemotherapy period.” NCT03498326 ↗ “standard background therapy consisting of celecoxib 0.2g orally once daily” NCT07632599 ↗ “including oral celecoxib, topical diclofenac, and other skin protectants” NCT06602167 ↗ “placebo tablets BID plus celecoxib 200 mg orally once daily for 12 weeks” PMID 38869746 ↗ Jun 2024 “Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery” NCT01545141 ↗ “single 4.8 mL dose of 120-mg celecoxib oral solution or placebo” PMID 34447267 ↗ Aug 2021 “200 mg celecoxib (Celebra®, Pfizer) is given p.o. every day” NCT00197912 ↗ “NSAIDs: ibuprofen, celecoxib, or diclofenac/misoprostol” NCT01943435 ↗ “Metformin 1000mg tablet plus celecoxib 200 mg capsule” NCT04767841 ↗ “combination of Toripalimab,regorafenib and celecoxib” NCT05933980 ↗ “standard oral NSAIDs (e.g., ibuprofen or celecoxib)” NCT07353372 ↗ “625 mg intra-articular sustained-release celecoxib” NCT05603832 ↗ “Single dose 150 mg celecoxib as formulation D1” NCT00925106 ↗ “YYC301-1: Tramadol 37.5Mg+ Celecoxib 200mg” NCT05362851 ↗ “A long-acting formulation of celecoxib” NCT07338266 ↗ “Celecoxib Dosage: 200 mg per tablet” NCT06420388 ↗ “Celecoxib 200g 1 hour before surgery” NCT07116564 ↗ “COX-2 inhibitor (Celecoxib)” NCT03391570 ↗ “Celecoxib 200 mg/24 hours” NCT04648540 ↗ “celecoxib 100 mg BID” NCT03062644 ↗ “200 mg celecoxib qd” NCT00665431 ↗ “10. COX2: Celecoxib” NCT02101385 ↗ “Celecoxib 400mg” NCT03549611 ↗ “celecoxib” NCT00849966 ↗ “Celecoxib” NCT01638962 ↗ “Celecoxib” NCT03885596 ↗ |
| Known as | AD-2111 | “Purpose: pharmacokinetic interactions and safety of AD-2111 and AD-2112 in healthy adult volunteers Condition or disease : Pain Intervention/treatment Drug : AD-2111(Celecoxib...” NCT04375865 ↗ |
| Known as | CBX | “using celecoxib (CBX), a cyclooxygenase 2 (COX-2) inhibitor” PMID 31630035 ↗ Oct 2019 |
| Known as | CEL | “celecoxib (CEL) (200 mg) given once daily versus placebo in knee osteoarthritis (OA).” PMID 26313454 ↗ Aug 2015 |
| Known as | CELBESTA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02780323 ↗ |
| Known as | Celeberex | “Celecoxib is a nonsteroidal anit-inflammatory drug (NSAID) marketed worldwide (in the United States \[US\] as Celeberex) and approved for the relief of signs and symptoms of...” NCT00424294 ↗ |
| Known as | Celebra | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03068260 ↗ |
| Known as | celebra (celecoxib) | “celebra (celecoxib)” NCT01756989 ↗ |
| Known as | Celebrex | “This study will investigate the benefits of administering celecoxib (Celebrex), a selective cyclooxygenase -2 (COX-2) inhibitor, in treating osteoarthritis (OA) subjects...” NCT00359151 ↗67“This 2-part study will evaluate the effectiveness and side effects of two anti-inflammatory drugs for relieving pain and improving jaw function in patients with...” NCT00001955 ↗ “The selective cyclo-oxygenase 2 (COX-2) inhibitor, celecoxib (Celebrex, Pfizer Inc.), is being investigated as an anticancer agent in chemoprevention and adjuvant therapeutic...” NCT00596219 ↗ “Group I who will receive Tramadol 100mg (Trama SR®, Global Napi) orally 1 hour before the procedure, group II who will receive Celecoxib 200mg (Celebrex® 200, Pfizer) 1 hour...” NCT02071303 ↗ “The patients whose endometrial biopsy shows grade 2 or 3 endometrioid-type, clear cell, and papillary serous types of uterine cancers will be put on a selective COX-II...” NCT00231829 ↗ “A Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of Once Daily Celebrex® (Celecoxib) vs. Placebo in the Treatment of Subjects With Osteoarthritis of...” NCT00640627 ↗ “A Double-Blind, Placebo-Controlled, Randomized Comparison Study of the Efficacy of Celebrex 400 mg Single Dose Pre and Celebrex 200 mg Post Ambulatory Arthroscopic Knee Surgery...” NCT00633438 ↗ “In addition, we aim to determine the effect of celecoxib (Celebrex) on tumour oxygenation, interstitial fluid pressure, COX-2 levels, prostaglandin E2 levels, angiogenesis and...” NCT00152828 ↗ “To determine if Celebrex (Celecoxib) is as effective as Toradol (Ketorolac) at controlling postoperative pain when given in addition to standard postoperative pain control regimens.” NCT03331315 ↗ “A Double-Blind, Placebo-Controlled, Randomized 24-Month Study, Assessing The Effect Of Celecoxib (Celebrex) Long Term Treatment On Hip Osteoarthritis (OA) Progression OSCARE” NCT00163241 ↗ “A Phase II Trial Of Celecoxib (Celebrex) And Capecitabine (Xeloda) Combined With Pelvic Irradiation As Neoadjuvant Treatment Of Stage II or III Adenocarcinoma Of The Rectum” NCT00081224 ↗ “A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128.” PMID 17084549 ↗ Nov 2006 “A Phase I Trial of Postoperative Radiation With Dose-Escalation of A Cox-2 Inhibitor, Celebrex™ (CELECOXIB) in Patients With Soft Tissue Sarcoma of the Extremity” NCT00450736 ↗ “Effectiveness and Safety of Celecoxib (Celebrex 200 mg) Combined With Joins in the Treatment of Degenerative Knee Osteoarthritis: a Randomized Controlled Trial” NCT04718649 ↗ “BAT1306 100mg /pembrolizumab 200mg on day 1 + aspirin 200mg oral (celebrex 400mg oral when there is contraindication to aspirin) on day 1-21 every three weeks” NCT03638297 ↗ “Celebrex (Celecoxib) is a nonsteroidal anti-inflammatory drug (NSAID) that is used to treat arthritis, pain, menstrual cramps, and colonic polyps.” NCT00598234 ↗ “Drug generic names: celecoxib (celebrex), naproxen/esomeprazole (vimovo), acetaminophen/tramadol (ultracet ER), oxycodone/naloxone (targin)” NCT02307305 ↗ “Celecoxib (Celebrex®) is a drug that lessens the action of an enzyme called cyclooxygenase-2 (COX-2) also known as a "COX-2 inhibitor".” NCT00188565 ↗ “Once Daily Celebrex (Celecoxib) and Naproxen 500 mg Twice Daily in the 6-month Treatment of Subjects With Osteoarthritis of the Knee” NCT00643799 ↗ “Celebrex (also called Celecoxib) is an oral medication that is approved by the FDA for pain in the treatment of arthritis.” NCT00183807 ↗ “Drug generic names: celecoxib (celebrex), Pregabalin (Lyrica), acetaminophen/tramadol (ultracet ER), oxycodone (Ircodon)” NCT02600247 ↗ “The study drugs are a combination of celecoxib (Celebrex®), Interferon-α2b (IFN), and rintatolimod (Ampligen®), or CKM.” NCT02615574 ↗ “Patients were treated with sorafenib taking capsules celecoxib (Celebrex) at the same time, 200mg/day, last 6 months” NCT02961998 ↗ “A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects” NCT00807846 ↗ “non-steroid anti-inflammatory drugs (NSAID):"celecoxib", "Celebrex®" 0.2g Bid(twice a day),PO (Per Os)” NCT01709656 ↗ “Celebrex(celecoxib, pfizer) 200mg twice daily is administered for 5 days before FMD measurement.” NCT02255006 ↗ “starts thalidomide (50) 4# per day and celecoxib (Celebrex)(200) 2# bid for three weeks” NCT00934739 ↗ “Celecoxib (Celebrex®, G.D. Searle \& Co., Chicago, IL), one 200 mg oral capsule QD” NCT00904605 ↗ “Once Daily Celebrex (Celecoxib) and Three Times Daily Ibuprofen vs. Placebo” NCT00630929 ↗ “Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer” NCT00136487 ↗ “commercial formulation of celecoxib 400-mg oral capsules (Celebrex®)” PMID 28748412 ↗ Oct 2017 “celecoxib (Celebrex) 400 mg one hour prior to surgery or placebo” NCT03305068 ↗ “Celecoxib (Celebrex) is an FDA approved drug to treat arthritis.” NCT00215345 ↗ “Celebrex 400mg PO, Lyrica 75mg x1 dose pre-op, Tramadol 50mg x 1” NCT06113211 ↗ “Celebrex cap. (celecoxib 200mg) : once daily, for 12 weeks” NCT01768520 ↗ “Celebrex: po, 200mg, qd, six weeks” NCT00602901 ↗ “Celecoxib (Celebrex)” NCT07104266 ↗ “Celecoxib (Celebrex)” NCT00007189 ↗ “Celecoxib (Celebrex)” NCT00846430 ↗ “Drug: Celebrex” NCT02456363 ↗ “Celebrex” NCT02602509 ↗ |
| Known as | Celebrex (Registered Trademark) | “This study will determine whether the drug celecoxib (Celebrex® (Registered Trademark)) can help stabilize or improve vision in patients with age-related macular degeneration...” NCT00043680 ↗ |
| Known as | Celebrex200 | “will receive oral Celecoxib 200 mg capsule (Celebrex®200, Pfizer, USA) once 3 hours before the colposcopic guided biopsy” NCT03464552 ↗6“Celecoxib 200 mg (Celebrex® 200, Pfizer,USA) administered orally immediately, 12 h and 24 h after randomization.” NCT03694873 ↗ “Celecoxib 200mg (Celebrex® 200, Pfizer, USA) in addition to a placebo similar to hyoscine butyl bromide” NCT03499743 ↗ “Women will receive Celecoxib 200mg (Celebrex® 200, Pfizer, USA) orally 2 hours before IUD insertion.” NCT02827487 ↗ “Celecoxib 200mg (Celebrex® 200, Pfizer, USA) in addition to a placebo similar to Tramadol” NCT02736019 ↗ “Celecoxib 200 mg (Celebrex® 200, Pfizer,USA) administered orally 2 h before the procedure” NCT04505657 ↗ “one capsule of Celecoxib 200 mg (Celebrex 200, Pfizer, USA) simultaneously.” NCT05911126 ↗ |
| Known as | celecoxib (Celebrex) | “celecoxib (Celebrex®)” NCT02615574 ↗4“celecoxib (Celebrex)” NCT01769625 ↗ “celecoxib (Celebrex)” NCT01425476 ↗ “Celecoxib: Celebrex” NCT01344213 ↗ “celecoxib(celebrex)” NCT00526214 ↗ |
| Known as | Celecoxib, ATC M01AH01 | “Celecoxib, ATC M01AH01” NCT05415397 ↗ |
| Known as | Celecoxib, Celebra, Pfizer | “Celecoxib, Celebra®, Pfizer” NCT00197912 ↗ |
| Known as | CTC | “BACKGROUND: STARDOM2 is a randomized, double-blind, phase 3 trial evaluating the efficacy and safety of co-crystal of tramadol-celecoxib (CTC)-a first-in-class analgesic...” PMID 35974668 ↗ Sep 2022 |
| Known as | CXB | “We conducted a randomised trial of celecoxib (CXB) versus CXB+diflouromethylornithine (DFMO) to determine the synergistic effect, if any.” PMID 25792707 ↗ Mar 2015 |
| Known as | Drug: Celebrex | “Drug: Celebrex” NCT02456363 ↗ |
| Known as | ELYXYB | “Celecoxib Oral Solution (ELYXYB)” PMID 34447267 ↗ Aug 2021 |
| Known as | Episcleral Celecoxib | “Drug: Episcleral Celecoxib” NCT04120636 ↗ |
| Known as | F14 | “This is a Phase 3, randomized, double blind, multicenter study to evaluate the analgesic efficacy and safety of a single intra-articular dose of F14 (625 mg sustained release...” NCT05603832 ↗1“Drug: F14 (sustained release celecoxib)” NCT04860635 ↗ |
| Known as | HD042 | “the HD042 (Celecoxib) at 20uM concentration can inhibit HBV DNA, HBsAg and HBeAg by 70.87%, 88.52% and 87.55% respectively, without significant cytotoxicity.” NCT05256823 ↗ |
| Known as | MR308 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02982161 ↗ |
| Known as | SC-58635 | “Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps” NCT00141193 ↗3“Clinical Protocol For A Phase II Double-Blind, Placebo-Controlled, Randomized Study Of Celecoxib (Sc-58635) In Oral Premalignant Lesions, Investigator IND” NCT00036283 ↗ “Clinical Protocol for an Open Label Study of Celecoxib (SC-58635) on the Acute Effect of Human UV-Irradiation” NCT02090933 ↗ “Celecoxib (SC-58635)” NCT00001693 ↗ |
| Known as | YM177 | “celecoxib (YM177) 200 mg bid” NCT00141154 ↗ |
| Action | Inhibit | “Celecoxib, is in oral anti-inflammatory and analgesic agent that acts by selectively inhibiting cyclooxygenase 2 (COX-2)” NCT00001955 ↗ |
| Modality | Other / unclassified | “celecoxib, an NSAID purposefully designed to selectively inhibit COX-2” PMID 22278334 ↗ Jan 2012 |
| Route | Oral | “Celecoxib (to be provided by Searle) will be administered at 200mg p.o. BID x 12 months or 400mg p.o. BID x 12 months” NCT00001693 ↗ |
| Target | PTGS2 | “Phase II Double-Blind, Placebo Controlled, Randomized Study Of Celecoxib, A Selective COX-2 Inhibitor, In Oral Premalignant Lesions” NCT00014404 ↗ |